Rivastigmine as a treatment in delirium; a pilot study

Completed

• Conditions: delirium stroke (dutch; delier beroerte)

• Registration Number: NL-OMON28018
• Lead Sponsor: ovartis

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

1. Recent stroke

2. Persistent delirium

Exclusion Criteria

1. Prior adverse effects of rivastigmine

2. Severe renal failure

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Presence of delirium measured with confusion assessment method and delirium rating scal

Secondary Outcome Measures

Name	Time	Method
- Duration of delirium <br /><br>- Other medication needed